Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Current Assets (2016 - 2025)

Viking Therapeutics' Current Assets history spans 12 years, with the latest figure at $715.6 million for Q4 2025.

  • For Q4 2025, Current Assets fell 21.12% year-over-year to $715.6 million; the TTM value through Dec 2025 reached $715.6 million, down 21.12%, while the annual FY2025 figure was $715.6 million, 21.12% down from the prior year.
  • Current Assets for Q4 2025 was $715.6 million at Viking Therapeutics, down from $738.7 million in the prior quarter.
  • Across five years, Current Assets topped out at $966.3 million in Q1 2024 and bottomed at $149.5 million in Q1 2023.
  • The 5-year median for Current Assets is $374.3 million (2023), against an average of $491.4 million.
  • The largest annual shift saw Current Assets dropped 26.37% in 2022 before it surged 546.52% in 2024.
  • A 5-year view of Current Assets shows it stood at $210.5 million in 2021, then fell by 20.66% to $167.0 million in 2022, then surged by 119.84% to $367.2 million in 2023, then soared by 147.05% to $907.2 million in 2024, then fell by 21.12% to $715.6 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Current Assets are $715.6 million (Q4 2025), $738.7 million (Q3 2025), and $827.0 million (Q2 2025).